21shares XRP ETF (TOXR) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TOXR SEC filings page.
This page shows 21shares XRP ETF (TOXR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
The reported profile is an equity-funded vehicle with a substantial accounting loss and virtually no recorded liabilities.
FY2025 net loss of-$36.0M translated into return on assets of-14.5% . Return on equity of-14.6% was nearly identical because total liabilities were just$35K , leaving the vehicle financed almost entirely by equity.
With total assets of
That distinction matters: the reported loss cannot be attributed to sales volume, cost structure, or reinvestment from these fields, while the near-zero leverage shows the loss is not being amplified by debt financing.
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
21shares XRP ETF does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
21shares XRP ETF reported -$32.9M in net income in Q2 2026. This represents a decrease of 308.4% from the same quarter a year earlier. Against the prior quarter it is up 37.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
21shares XRP ETF's ROE was -29.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 36.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
TOXR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
TOXR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $112.9M | $142.2M | $247.7M+18.2% | $280.0M | N/A | N/A | $209.5M |
| Total Liabilities | $6K | $6K | $35K-77.7% | $133K | N/A | N/A | $158K |
| Total Equity | $112.9M-49.9% | $142.1M-32.1% | $247.7M+18.3% | $279.9M | $225.2M | $209.4M | $209.4M |
| Retained Earnings | -$132.6M | -$99.7M | -$47.3M-318.1% | $59.2M | N/A | N/A | -$11.3M |
Not reported in any period shown, so not listed: Current Assets, Cash & Equivalents, Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
TOXR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.